Patents by Inventor Andrei Leonov

Andrei Leonov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN
    Publication number: 20230067910
    Abstract: The present invention relates to compounds represented by general formula (Ia), (Ib), (IIa) or (IIb). These compounds are suitable for imaging alpha-synuclein and for diagnosing diseases which are associated with the aggregation of alpha-synuclein. The compounds are also useful for treating and preventing diseases which are associated with the aggregation of alpha-synuclein.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 2, 2023
    Applicants: MODAG GMBH, MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Armin GIESE, Felix SCHMIDT, Daniel WECKBECKER, Andrei LEONOV, Sergey RYAZANOV, Christian GRIESINGER, Bernd PICHLER, Kristina HERFERT, Andreas MAURER, Laura KÜBLER, Sabrina BUSS
  • Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
    Patent number: 11180518
    Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: November 23, 2021
    Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN
    Inventors: Dorothea Becker, Thomas M. Jovin, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Armin Giese, Tiago F. Outeiro, Diana F. Lazaro, Michael P. Schön, Margarete Schön
  • PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA
    Publication number: 20200165279
    Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 28, 2020
    Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN
    Inventors: Dorothea BECKER, Thomas M. JOVIN, Christian GRIESINGER, Andrei LEONOV, Sergey RYAZANOV, Armin GIESE, Tiago F. OUTEIRO, Diana F. LAZARO, Michael P. SCHÖN, Margarete SCHÖN
  • Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
    Patent number: 10435373
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: October 8, 2019
    Assignees: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick née Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
  • Water-soluble derivatives of 3,5-diphenyl-diazole compounds
    Patent number: 10308671
    Abstract: The present invention is concerned with derivatives of 3,5-diphenyl-diazole compounds, which are effective therapeutic agents for use in treating diseases linked to protein aggregation and/or neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob disease (CJD). The therapeutic effect is caused by the inhibition of the protein aggregation in the affected tissue, such as the brain. 3,5-Diphenyl-diazole derivatives have been shown to be effective in inhibiting aggregation of proteins but are also characterized by their poor solubility in aqueous solutions. The prodrugs of the invention are modified 3,5-diphenyl-diazole derivatives, which are characterized by their improved solubility in aqueous solutions, and by their increased bioavailability.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: June 4, 2019
    Assignee: Max-Planck-Gesellschaft zur Forderung
    Inventors: Armin Giese, Felix Schmidt, Christian Griesinger, Andrei Leonov, Sergey Ryazanov
  • WATER-SOLUBLE DERIVATIVES OF 3,5-DIPHENYL-DIAZOLE COMPOUNDS
    Publication number: 20180370997
    Abstract: The present invention is concerned with derivatives of 3,5-diphenyl-diazole compounds, which are effective therapeutic agents for use in treating diseases linked to protein aggregation and/or neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob disease (CJD). The therapeutic effect is caused by the inhibition of the protein aggregation in the affected tissue, such as the brain. 3,5-Diphenyl-diazole derivatives have been shown to be effective in inhibiting aggregation of proteins but are also characterized by their poor solubility in aqueous solutions. The prodrugs of the invention are modified 3,5-diphenyl-diazole derivatives, which are characterized by their improved solubility in aqueous solutions, and by their increased bioavailability.
    Type: Application
    Filed: December 14, 2016
    Publication date: December 27, 2018
    Applicants: Max-Planck-Gesellschaft zur Förderung
    Inventors: Armin GIESE, Felix SCHMIDT, Christian GRIESINGER, Andrei LEONOV, Sergey RYAZANOV
  • DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    Publication number: 20180346426
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Application
    Filed: August 3, 2018
    Publication date: December 6, 2018
    Applicants: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V.
    Inventors: Armin GIESE, Uwe BERTSCH, Hans KRETZSCHMAR, Matthias HABECK, Thomas HIRSCHBERGER, Paul TAVAN, Christian GRIESINGER, Andrei LEONOV, Sergey RYAZANOV, Petra FRICK née WEBER, Markus GEISSEN, Martin H. GROSCHUP, Jens WAGNER
  • Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
    Patent number: 10071966
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 11, 2018
    Assignees: LUDWIG-MAXIMALIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick, Markus Geissen, Martin H. Groschup, Jens Wagner
  • DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    Publication number: 20160185730
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Application
    Filed: December 22, 2015
    Publication date: June 30, 2016
    Applicants: Ludwig-Maximilians-Universität München, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick née Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
  • NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    Publication number: 20110293520
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R1)(R2)—, —C(R3)?, —N(R4)—, —N?, —N+(R5)?, —O— and —S—; M and Z are independently nondirectionally selected from formula (I) and formula (II).
    Type: Application
    Filed: June 9, 2009
    Publication date: December 1, 2011
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Mathias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
  • Software based Internet/Television convergence methods and systems for organizing and displaying Internet media content on computers and Television sets
    Publication number: 20100017821
    Abstract: Convergence systems described in the prior art typically focus on advancing hardware architecture. Such systems provide limited solutions as consumers are restricted to the use of proprietary networks, incur significant extra costs upgrading their equipment and pay subscription fees. General public demands low cost solutions for the consumption of the Internet media content in a traditional TV watching experience in the living room. The present invention provides a software-based solution and includes methods, systems, and software codes for a cost effective delivery and organization of multimedia content, informational feeds and interactive advertisements transmitted over the Internet to the user's TV and/or entertainment system already present in the user's home or office. This invention will further advance the convergence of the Internet, portable screen-based media devices, land line and mobile telephones, and traditional television communication channels.
    Type: Application
    Filed: July 21, 2008
    Publication date: January 21, 2010
    Inventors: Andrei A. Leonov, Leonard Bensonoff
  • Method of preparing lithium complex salts for use in electrochemical cells
    Patent number: 6864017
    Abstract: The invention relates to a method of preparing lithium complex salts and their intermediaries and to the use of these in electrolytes.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: March 8, 2005
    Assignee: Merck Patent GmbH
    Inventors: Andrei Leonov, Armin de Meijere, Michael Schmidt
  • Method of preparing lithium complex salts for use in electrochemical cells
    Publication number: 20040091785
    Abstract: The invention relates to a method of preparing lithium complex salts and their intermediaries and to the use of these in electrolytes.
    Type: Application
    Filed: October 31, 2003
    Publication date: May 13, 2004
    Inventors: Andrei Leonov, Armin de Meijere, Michael Schmidt
  • Method of preparing lithium complex salts for use in electrochemical cells
    Patent number: 6657072
    Abstract: The invention relates to a method of preparing lithium complex salts and their intermediaries and to the use of these in electrolytes.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: December 2, 2003
    Assignee: Merck Patent Gesellschaft mit beschränkter Haftung
    Inventors: Andrei Leonov, Armin de Meijere, Michael Schmidt
  • Method of preparing lithium complex salts for use in electrochemical cells
    Publication number: 20030028023
    Abstract: The invention relates to a method of preparing lithium complex salts and their intermediaries and to the use of these in electrolytes.
    Type: Application
    Filed: July 10, 2002
    Publication date: February 6, 2003
    Inventors: Andrei Leonov, Armin de Meijere, Michael Schmidt
  • Method of preparing lithium complex salts for use in electrochemical cells
    Patent number: 6441216
    Abstract: The invention relates to a method of preparing lithium complex salts and their intermediaries and to the use of these in electrolytes.
    Type: Grant
    Filed: July 10, 2000
    Date of Patent: August 27, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Andrei Leonov, Armin de Meijere, Michael Schmidt